Product Description
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Obstetric Labor, Premature|Pregnancy Outcomes
Phase 2: Obstetric Labor, Premature|Healthy Volunteers
Phase 1: Obstetric Labor, Premature|Premature Ejaculation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Follow-Up Study to Assess Long-Term Safety of Infants and Children exposed to Retosiban | P3 |
Completed |
Pregnancy Outcomes |
2019-09-02 |
|
| ARIOS | P3 |
Completed |
Obstetric Labor, Premature |
2019-09-02 |
|
| JapicCTI-163259 | P3 |
Completed |
Obstetric Labor, Premature |
2019-06-05 |
|
| Study comparing the Efficacy and Safety of Retosiban Versus Atosiban in Spontaneous Preterm labor | P3 |
Completed |
Pregnancy Outcomes |
2017-08-25 |